Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Pharmacy Reports
Pradana, Radiktya Surya
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Isatin come on the stage of CDK4/6 inhibitor Pradana, Radiktya Surya; Fareza, Muhammad Salman
Pharmacy Reports Vol. 2 No. 2 (2022): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.12

Abstract

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved the prognosis for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, including those with metastatic or advanced breast cancer (mBC/ABC). Recent research has focused on developing CDK4/6 inhibitors with diverse structural frameworks, including isatin-based compounds. Isatin and its derivatives have shown promise in inhibiting CDK4/6, with potential efficacy against breast cancer cell lines. Studies have also indicated that isatinyl-2-aminobenzoylhydrazone (ISABH) complexes, particularly those with transition metals like nickel (Ni-ISABH), exhibit strong binding affinities to CDK6 and fulfill key pharmacokinetic criteria.
Co-Authors Fareza, Muhammad Salman